$JAGSNPHARM

In the pharma space, Jagsonpal saw decent buying from Promoters and FIIs between January and March. The stock has been in a downward trend but is now approaching a critical rejection zone. We need to see specific price action here to confirm if the trend has truly reversed. My take is a bit more cautious on this one. While the insider buying is a positive signal, the pharma sector requires much more precision. It hasn’t shown the same "strength" as Diffusion or RateGain yet. Keep it on your secondary watchlist; it’s a "maybe" until it clears the immediate hurdles. Only a clear price breakout would make this worth the risk.